Avalo Therapeutics (AVTX) Non-cash Items (2015 - 2016)
Avalo Therapeutics (AVTX) reported Non-cash Items of $657099.0 for Q3 2016, up 49.47% on a YoY basis from $439607.0 in Q4 2015, and up 2.27% quarter-over-quarter from $642541.0 in Q2 2016.
Avalo Therapeutics (AVTX) Non-cash Items (2015 - 2016) Analysis & Trends
Avalo Therapeutics has reported Non-cash Items for 2 years, with the latest figure at $657099.0 in Q3 2016.
- For the quarter ending Q3 2016, Non-cash Items rose 49.47% year-over-year to $657099.0; the trailing twelve-month figure through Sep 2016 stood at $657099.0 (up 49.47% YoY), and the FY2015 full-year result was $604167.0, changed N/A from the prior year.
- Non-cash Items for Q3 2016 stood at $657099.0, up from $642541.0 in the prior quarter.
- The five-year high for Non-cash Items was $657099.0 in Q3 2016, with the low at $439607.0 in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Avalo Therapeutics | 296.38 Mn | 296.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 657,099.00 |
| Sep 30, 2016 | 657,099.00 |
| Jun 30, 2016 | 642,541.00 |
| Jun 30, 2016 | 642,541.00 |
| Mar 31, 2016 | 606,647.00 |
| Mar 31, 2016 | 606,647.00 |
| Dec 31, 2015 | 604,167.00 |
| Dec 31, 2015 | 604,167.00 |
| Sep 30, 2015 | 439,607.00 |
| Sep 30, 2015 | 439,607.00 |